Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Fritsche

Showing results (81-90 of 214) with videos related to

Pageof 22
Sort By:
Diagnostic Microbiology and Infectious Disease|August 18, 2005
Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unitHelio S Sader, Ronald N Jones, Michael J Dowzicky, et al.
Journal of Chemotherapy (Florence, Italy)|March 18, 2008
Activity of daptomycin and selected antimicrobial agents tested against Staphylococcus aureus from patients with bloodstream infections hospitalized in European medical centersH S Sader, A A Watters, T R Fritsche, et al.
The Journal of Infectious Diseases|November 1, 1989
Praziquantel for treatment of human Nanophyetus salmincola (Troglotrema salmincola) infectionT R Fritsche, R L Eastburn, L H Wiggins, et al.
Journal of Clinical Microbiology|October 6, 2006
Contemporary prevalence of BRO beta-lactamases in Moraxella catarrhalis: report from the SENTRY antimicrobial surveillance program (North America, 1997 to 2004)Lalitagauri M Deshpande, Helio S Sader, Thomas R Fritsche, et al.
Diagnostic Microbiology and Infectious Disease|August 28, 2007
LEADER surveillance program results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from the United States (50 medical centers)Ronald N Jones, Thomas R Fritsche, Helio S Sader, et al.
International Journal of Antimicrobial Agents|May 16, 2006
Evaluation of dalbavancin in combination with nine antimicrobial agents to detect enhanced or antagonistic interactionsDavid M Johnson, Thomas R Fritsche, Helio S Sader, et al.
The Journal of Antimicrobial Chemotherapy|April 2, 2004
Potential utility of a peptide deformylase inhibitor (NVP PDF-713) against oxazolidinone-resistant or streptogramin-resistant Gram-positive organism isolatesRonald N Jones, Gary J Moet, Helio S Sader, et al.
International Journal of Antimicrobial Agents|August 4, 2004
Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001)Jennifer M Streit, Ronald N Jones, Helio S Sader, et al.
Diagnostic Microbiology and Infectious Disease|August 18, 2004
Antimicrobial resistance rates and clonality results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) programme: report of year five (2003)Paul R Rhomberg, Ronald N Jones, Helio S Sader, et al.
Diagnostic Microbiology and Infectious Disease|February 7, 2006
Microbiologic characterization of isolates from a dalbavancin clinical trial for catheter-related bloodstream infectionsBeth P Goldstein, Ronald N Jones, Thomas R Fritsche, et al.
Pageof 22

Showing results (81-90 of 214) with videos related to

Sort By:
Pageof 22
Diagnostic Microbiology and Infectious Disease|August 18, 2005
Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unitHelio S Sader, Ronald N Jones, Michael J Dowzicky, et al.
Journal of Chemotherapy (Florence, Italy)|March 18, 2008
Activity of daptomycin and selected antimicrobial agents tested against Staphylococcus aureus from patients with bloodstream infections hospitalized in European medical centersH S Sader, A A Watters, T R Fritsche, et al.
The Journal of Infectious Diseases|November 1, 1989
Praziquantel for treatment of human Nanophyetus salmincola (Troglotrema salmincola) infectionT R Fritsche, R L Eastburn, L H Wiggins, et al.
Journal of Clinical Microbiology|October 6, 2006
Contemporary prevalence of BRO beta-lactamases in Moraxella catarrhalis: report from the SENTRY antimicrobial surveillance program (North America, 1997 to 2004)Lalitagauri M Deshpande, Helio S Sader, Thomas R Fritsche, et al.
Diagnostic Microbiology and Infectious Disease|August 28, 2007
LEADER surveillance program results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from the United States (50 medical centers)Ronald N Jones, Thomas R Fritsche, Helio S Sader, et al.
International Journal of Antimicrobial Agents|May 16, 2006
Evaluation of dalbavancin in combination with nine antimicrobial agents to detect enhanced or antagonistic interactionsDavid M Johnson, Thomas R Fritsche, Helio S Sader, et al.
The Journal of Antimicrobial Chemotherapy|April 2, 2004
Potential utility of a peptide deformylase inhibitor (NVP PDF-713) against oxazolidinone-resistant or streptogramin-resistant Gram-positive organism isolatesRonald N Jones, Gary J Moet, Helio S Sader, et al.
International Journal of Antimicrobial Agents|August 4, 2004
Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001)Jennifer M Streit, Ronald N Jones, Helio S Sader, et al.
Diagnostic Microbiology and Infectious Disease|August 18, 2004
Antimicrobial resistance rates and clonality results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) programme: report of year five (2003)Paul R Rhomberg, Ronald N Jones, Helio S Sader, et al.
Diagnostic Microbiology and Infectious Disease|February 7, 2006
Microbiologic characterization of isolates from a dalbavancin clinical trial for catheter-related bloodstream infectionsBeth P Goldstein, Ronald N Jones, Thomas R Fritsche, et al.
Pageof 22